NEW YORK, NY--(Marketwire - Oct 31, 2012) - With healthcare reform threatening to eat into sales for several companies, many in the medical appliances & equipment industry have been working hard to bring new products to market. Companies like Hologic Inc. and St. Jude Medical Inc. are working on a number of products, and those that can get FDA approval could outperform their peers in these difficult times. StBulls.com has initiated technical analysis on Hologic Inc. (
www.StBulls.com enthuses to bring the best from the internet under one roof, providing you with a one click opportunity to view what the market and financial researchers globally have to say about any particular bellwether stocks in any given financial environment. We work with a number of financial professionals and a dedicated team of researchers that use their acute knowledge to help you manage your understanding of the market. To be part of this community please sign up at
Hologic has had some recent success in regards to FDA approval, as the company announced that the FDA had approved its APTIMA HPV 16 18/45 Genotype Assay for use on its TIGRIS instrument system. The approval is the first for a test of genotyping human papillomavirus (HPV) types 16, 18 and/or 45, which are associated with about 80% of all invasive cervical cancers globally. Read our technical analysis on Hologic Inc. by clicking on
Earnings results in the industry have been mixed in the 3rd quarter, as fierce competition and a soft macroeconomic climate have weighed on results in some cases. St. Jude Medical had a challenging quarter, as its net sales contracted by 4% when compared to the same period last year. Investors looking for technical analysis on St. Jude Medical Inc. are encouraged to use the link below
About Street Bulls
STREET BULLS is committed to provide the investor community with sharp and timely trading and investing advice. Our aim is to help our readers achieve above-average returns from the markets and create wealth for themselves. Whether you are a first time investor, a seasoned pro, an "in and out" day trader or a long-term investor, our newsletters and trading advice will provide you with the information you need for success in today's volatile markets.
To view our disclaimer, use this link